Content about Pharmaceuticals in India

August 17, 2012

Ranbaxy Labs has launched an authorized generic version of a diabetes drug made by Takeda Pharmaceutical, Ranbaxy said Friday.

PRINCETON, N.J. — Ranbaxy Labs has launched an authorized generic version of a diabetes drug made by Takeda Pharmaceutical, Ranbaxy said Friday.

Ranbaxy announced the launch, through subsidiary Ranbaxy Pharmaceuticals and under an agreement with Takeda, of pioglitazone hydrochloride tablets, an authorized generic version of Takeda's Actos. An authorized generic is a branded drug marketed at a reduced price under its generic name, typically by a third-party company operating under contract with the original branded drug's manufacturer.

August 9, 2012

Drug maker Sagent Pharmaceuticals has launched a generic chemotherapy drug, the company said Thursday.

SCHAUMBURG, Ill. — Drug maker Sagent Pharmaceuticals has launched a generic chemotherapy drug, the company said Thursday.

Sagent announced the launch of oxaliplatin, a generic version of Sanofi's Eloxatin.

Various versions of the drug had sales of about $1.7 billion during the 12-month period ended in June, according to IMS Health.


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

August 6, 2012

Generic drug maker Amneal Pharmaceuticals will spend $120 million to expand three of its plants, the company said Monday.

BRIDGEWATER, N.J. — Generic drug maker Amneal Pharmaceuticals will spend $120 million to expand three of its plants, the company said Monday.

Amneal said it would spend the money over a two-year period lasting through 2014 to "significantly" grow operations at research-and-development, manufacturing and distribution plants in New York, New Jersey and Kentucky. The company, which employs more than 1,100 people in the United States, said the expansion would create 500 more jobs.

July 31, 2012

AmerisourceBergen on Tuesday announced that it has signed a three-year agreement to supply approximately $18.5 billion in pharmaceuticals to Express Scripts on an annual basis.

VALLEY FORGE, Pa. — AmerisourceBergen on Tuesday announced that it has signed a three-year agreement to supply approximately $18.5 billion in pharmaceuticals to Express Scripts on an annual basis. The agreement is effective Oct. 1.

“We are honored that Express Scripts has chosen AmerisourceBergen to supply the brand pharmaceuticals it needs for its recently combined mail-order and specialty pharmacy business,” said Steven Collis, AmerisourceBergen president and CEO.

May 30, 2012

The Food and Drug Administration has approved a branded acne drug made by Ranbaxy Labs, the drug maker said.

PRINCETON, N.J. — The Food and Drug Administration has approved a branded acne drug made by Ranbaxy Labs, the drug maker said.

Ranbaxy announced the FDA approval of Absorica (isotretinoin), a drug for treating severe recalcitrant nodular acne. The company expects to launch Absorica in the United States in fourth quarter 2012 under an agreement with Canada-based Cipher Pharmaceuticals.

April 19, 2012

A trade organization representing generic drug manufacturers announced Thursday its latest solution to the problem of drug shortages.

WASHINGTON — A trade organization representing generic drug manufacturers announced Thursday its latest solution to the problem of drug shortages.

April 18, 2012

Valeant Pharmaceuticals International is acquiring "certain assets" of a drug maker based in Mexico.

MONTREAL — Valeant Pharmaceuticals International is acquiring "certain assets" of a drug maker based in Mexico.

Valeant said Wednesday that it would buy gastric, analgesic and anti-inflammatory drugs from branded generics manufacturer Atlantis Pharma for $71 million. The products had sales of $26 million last year.

April 10, 2012

Biotech manufacturer Amgen will acquire the private South San Francisco, Calif.-based drug developer Kai Pharmaceuticals for $315 million, the companies said Tuesday.

THOUSAND OAKS, Calif. — Biotech manufacturer Amgen will acquire the private South San Francisco, Calif.-based drug developer Kai Pharmaceuticals for $315 million, the companies said Tuesday.

The deal includes the acquisition of KAI-4169, an experimental drug Kai is developing for secondary hyperparathyroidism in patients with chronic kidney disease who are on dialysis. Amgen has provided a loan to fund phase-3 clinical studies of the drug and will acquire rights to it worldwide, except for Japan.

March 16, 2012

Another generic drug maker has joined efforts to challenge the patent on a drug made by Forest Labs for treating hypertension.

NEW YORK — Another generic drug maker has joined efforts to challenge the patent on a drug made by Forest Labs for treating hypertension.

March 14, 2012

Forest Labs has filed suit against Glenmark Generics and several other companies, alleging that they infringed on its patent for a drug to treat hypertension by seeking regulatory approval for generic versions.

NEW YORK — Forest Labs has filed suit against Glenmark Generics and several other companies, alleging that they infringed on its patent for a drug to treat hypertension by seeking regulatory approval for generic versions.

Forest and Johnson & Johnson subsidiary Janssen Pharmaceutica NV have sued Glenmark, Hetero USA, Torrent Pharmaceuticals and Watson Labs in response to their filing regulatory approval applications with the Food and Drug Administration for generic versions of Bystolic (nebivolol).

January 18, 2012

Patent expirations of key blockbuster drugs and efforts by payers to contain costs are likely to bring strong growth to the global generic drug market in the next few years as market-earned revenues grow by more than $100 billion, according to an analysis by research firm Frost & Sullivan.

LONDON — Patent expirations of key blockbuster drugs and efforts by payers to contain costs are likely to bring strong growth to the global generic drug market in the next few years as market-earned revenues grow by more than $100 billion, according to an analysis by research firm Frost & Sullivan.

The report, titled "Generic Pharmaceuticals Market — A Global Analysis" and focusing on the United States and Europe, also found that healthcare expenditure and sales revenues are poised to shift to India, China, Brazil, Turkey and South Korea.

January 18, 2012

Jazz Pharmaceuticals and Azur Pharma will become one company, the two drug makers said.

DUBLIN — Jazz Pharmaceuticals and Azur Pharma will become one company, the two drug makers said.

The two said the it now will be a specialty biopharmaceutical company called Jazz Pharmaceuticals plc and will be based in Dublin.

December 13, 2011

Generic drug maker Amneal Pharmaceuticals has added four new executives, the company said.

BRIDGEWATER, N.J. — Generic drug maker Amneal Pharmaceuticals has added four new executives, the company said.

Joseph Todisco has been appointed SVP global corporate strategy and business development. Previously serving as VP business development for Ranbaxy, Todisco will be responsible for the growth of Amneal's U.S. generics business and development of partnerships, mergers and acquisitions.

December 13, 2011

Though they've been on the market for less than a month, the generic and authorized generic versions of Pfizer's cholesterol-lowering drug Lipitor have captured more than one-tenth of prescriptions, according to published reports.

NEW YORK — Though they've been on the market for less than a month, the generic and authorized generic versions of Pfizer's cholesterol-lowering drug Lipitor have captured more than one-tenth of prescriptions, according to published reports.

Citing an analysis of data from IMS Health by J.P. Morgan, The Wall Street Journal reported that Ranbaxy's generic atorvastatin calcium tablets and Watson Pharmaceuticals' authorized generic have claimed about 14.6% of prescription volume since their launch on Nov. 30.

December 8, 2011

The Generic Pharmaceutical Association has appointed a new executive who will help guide the organization's newly created research and education institute.

WASHINGTON — The Generic Pharmaceutical Association has appointed a new executive who will help guide the organization's newly created research and education institute.

The organization announced Thursday the appointment of Ahaviah Glaser as VP policy and strategic alliances. Glaser previously was a member of AARP's government affairs team.

December 1, 2011

Ranbaxy Labs got the green light from the Food and Drug Administration Wednesday night to launch its generic version of Pfizer's cholesterol-lowering drug Lipitor.

SILVER SPRING, Md. — Ranbaxy Labs got the green light from the Food and Drug Administration Wednesday night to launch its generic version of Pfizer's cholesterol-lowering drug Lipitor.

The FDA announced the approval of Ranbaxy's atorvastatin calcium tablets in the 10-mg, 20-mg, 40-mg and 80-mg strengths. New Brunswick, N.J.-based Ohm Labs will manufacture the drug.

November 30, 2011

Ranbaxy Labs was supposed to launch its generic version of the world's top-selling drug Wednesday, but a competitor beat it to the punch as the former waits for final Food and Drug Administration clearance.

NEW YORK — Ranbaxy Labs was supposed to launch its generic version of the world's top-selling drug Wednesday, but a competitor beat it to the punch as the former waits for final Food and Drug Administration clearance.

November 22, 2011

Generic drug maker Par Pharmaceutical has promoted Thomas Haughey to president and Paul Campanelli to COO, the company said. The promotions take effect immediately.

WOODCLIFF LAKE, N.J. — Generic drug maker Par Pharmaceutical has promoted Thomas Haughey to president and Paul Campanelli to COO, the company said. The promotions take effect immediately.

"With the acquisition of Anchen and the pending acquisition of Edict, Par is becoming a larger and more complex organization with three diverse locations and more than 300 additional employees," Par chairman and CEO Patrick LePore said. "These new challenges and opportunities require a president and COO to effectively manage the company and its subsidiaries."

November 18, 2011

Par Pharmaceutical has completed its acquisition of Anchen Pharmaceuticals, the generic drug maker said.

WOODCLIFF LAKE, N.J. — Par Pharmaceutical has completed its acquisition of Anchen Pharmaceuticals, the generic drug maker said.

Par announced plans in August to acquire Irvine, Calif.-based Anchen for $410 million, consisting of a loan and cash it already had.

A privately owned company, Anchen has about 200 employees and more than 72,000 sq. ft. of manufacturing and warehouse space, Par said.

November 7, 2011

Third-quarter net revenue for Sagent Pharmaceuticals jumped 94% to $41.3 million, thanks to several new product launches during the period.

SCHAUMBURG, Ill. — Third-quarter net revenue for Sagent Pharmaceuticals jumped 94% to $41.3 million, thanks to several new product launches during the period.

Gross profit for the quarter ended Sept. 30 was $6.9 million, or 16.8% of net revenues, compared with $2.7 million, or 12.9% of net revenues, in the year-ago period.

November 2, 2011

AmerisourceBergen on Tuesday recorded revenues of $20.4 billion for fourth quarter 2011 ended Sept. 30, up 3.5%. Diluted earnings per share increased 8% to 54 cents. For the year, AmerisourceBergen posted $80.2 billion in revenue, up 2.9%.

VALLEY FORGE, Pa. — AmerisourceBergen on Tuesday recorded revenues of $20.4 billion for fourth quarter 2011 ended Sept. 30, up 3.5%. Diluted earnings per share increased 8% to 54 cents. For the year, AmerisourceBergen posted $80.2 billion in revenue, up 2.9%.

October 4, 2011

A wave of patent expirations over the next several years will open up a broad swath of drugs to generic competition, and India's Lupin Pharmaceuticals is looking to benefit, according to published reports.

NEW YORK — A wave of patent expirations over the next several years will open up a broad swath of drugs to generic competition, and India's Lupin Pharmaceuticals is looking to benefit, according to published reports.

The Wall Street Journal reported that the Mumbai-based company planned to launch 25 to 30 new generic drugs each year over the next couple of years.

September 16, 2011

Pharmacy benefit manager Express Scripts will provide services for patients using a drug to manage a debilitating side effect of many anti-cancer treatments, ESI said.

ST. LOUIS — Pharmacy benefit manager Express Scripts will provide services for patients using a drug to manage a debilitating side effect of many anti-cancer treatments, ESI said.

September 15, 2011

Insight Pharmaceuticals recently acquired the Monistat North American brand portfolio from McNeil and is establishing itself as the premier distributor of women's health over-the-counter products.

LANGHORNE, Pa. — Insight Pharmaceuticals recently acquired the Monistat North American brand portfolio from McNeil and is establishing itself as the premier distributor of women's health over-the-counter products.

September 8, 2011

Ranbaxy Labs will launch its generic version of the world's top-selling drug as originally planned, according to published reports.

NEW YORK — Ranbaxy Labs will launch its generic version of the world's top-selling drug as originally planned, according to published reports.

Citing Japan's Nikkei daily, Reuters reported that Gurgaon, India-based Ranbaxy would launch a generic version of Pfizer's cholesterol medication Lipitor (atorvastatin) at the end of November.